The U.S. Food and Drug Administration (FDA) approved the antiviral drug Veklury (Remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms for the treatment of COVID-19 requiring hospitalization. In a press release, the Medicines and Medical Devices Agency of Moldova says the FDA’s decision shows the U.S. Government’s confidence that this medicine can be safely and efficiently used to treat hospitalized patients, IPN reports.
Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval.
Earlier, the Medicines and Medical Devices Agency of Moldova authorized the import of about 7,000 bottles of Remdesivir, under the brand names Covifor and Desrem. In Moldova, Remdesivir is stipulated in the temporary national clinical protocol “Infection with the Novel Coronavirus” that is used to treat patients infected with Sars COV-2.
